Generic drugmakers want antitrust lawsuit dismissed

Six generic drugmakers are asking a federal judge in Connecticut to dismiss a 40-state lawsuit accusing them of artificially inflating and manipulating prices to reduce competition for antibiotic and oral diabetes medication.

The companies filed documents Monday citing a variety of reasons including that the states failed to adequately allege deceptive conduct and that the states lack standing to sue on behalf of their citizens.

The companies include Heritage Pharmaceuticals, of Eatontown, New Jersey; Aurobindo Pharma USA, of East Windsor, New Jersey; Citron Pharma, of East Brunswick, New Jersey; Mayne Pharma USA, of Raleigh, North Carolina; Mylan Pharmaceuticals of Canonsburg, Pennsylvania; and Teva Pharmaceuticals USA of North Wales, Pennsylvania.

Connecticut Attorney General George Jepsen says an investigation into "suspicious" generic drug price increases found evidence "of collusion and anticompetitive conduct" among drugmakers.

Explore further

Connecticut leads 20-state lawsuit over drug pricing

© 2017 The Associated Press. All rights reserved.

Citation: Generic drugmakers want antitrust lawsuit dismissed (2017, May 3) retrieved 4 August 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments